Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 6/20 | 0.57 |
| ▸ | HCRTR1 | O43613 | 10/20 | 0.49 |
| ▸ | HCRTR2 | O43614 | 10/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4233101 | 0.90 | HSD11B1 (0.50) | HSD11B1HCRTR1HCRTR2LMNATSHR | |
| SCHEMBL4222914 | 0.86 | HSD11B1 (0.60) | HSD11B1LMNATSHRNPSR1ALDH1A1 | |
| SCHEMBL4236491 | 0.86 | HSD11B1 (0.60) | HSD11B1LMNATSHRNPSR1ALDH1A1 | |
| SCHEMBL4228318 | 0.84 | HSD11B1 (0.56) | HSD11B1HCRTR1HCRTR2LMNATSHR | |
| SCHEMBL4151273 | 0.83 | HSD11B1 (0.63) | HSD11B1LMNATSHRNPSR1ALDH1A1 | |
| SCHEMBL4151267 | 0.83 | HSD11B1 (0.63) | HSD11B1LMNATSHRNPSR1ALDH1A1 | |
| SCHEMBL4233351 | 0.83 | MEN1 (0.59) | HSD11B1HCRTR1HCRTR2LMNATSHR | |
| SCHEMBL4232296 | 0.83 | HSD11B1 (0.61) | HSD11B1HCRTR1HCRTR2LMNATSHR | |
| SCHEMBL4636497 | 0.82 | HSD11B1 (0.42) | HSD11B1HCRTR1HCRTR2LMNANPSR1 | |
| SCHEMBL1968064 | 0.81 | HSD11B1 (0.53) | HSD11B1TSHRHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215822-A1 | Substituted Oxadiazole Derivatives as Positive Allosteric Modulators of Metabotropic Glutamate Receptors | NIKEM RESEARCH SRL (IT) | 2009-08-27 | — | — | US | claimed |
| US-20090215822-A1 | Substituted Oxadiazole Derivatives as Positive Allosteric Modulators of Metabotropic Glutamate Receptors | NIKEM RESEARCH SRL (IT) | 2009-08-27 | — | — | US | disclosed |
| US-20090215822-A1 | Substituted Oxadiazole Derivatives as Positive Allosteric Modulators of Metabotropic Glutamate Receptors | NIKEM RESEARCH SRL (IT) | 2009-08-27 | — | — | US | disclosed |
| US-20090215822-A1 | Substituted Oxadiazole Derivatives as Positive Allosteric Modulators of Metabotropic Glutamate Receptors | NIKEM RESEARCH SRL (IT) | 2009-08-27 | — | — | US | disclosed |
| EP-1893606-A2 | SUBSTITUTED OXADIAZOLE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Addex Pharma SA (CH) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006123255-A2 | SUBSTITUTED OXADIAZOLE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA SA (CH) | 2006-11-23 | — | — | WO | disclosed |
| WO-2006123255-A2 | SUBSTITUTED OXADIAZOLE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA SA (CH) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215822-A1 | Substituted Oxadiazole Derivatives as Positive Allosteric Modulators of Metabotropic Glutamate Receptors | GRM5, GRM3, GRM2 | HSD11B1 3080/4885HCRTR1 92/4885HCRTR2 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.